16.35
-0.04 (-0.24%)
| Previous Close | 16.39 |
| Open | 16.80 |
| Volume | 1,373,485 |
| Avg. Volume (3M) | 1,655,295 |
| Market Cap | 1,122,257,536 |
| Price / Earnings (Forward) | 1.11 |
| Price / Sales | 1.14 |
| Price / Book | 4.14 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 |
| Profit Margin | -10.21% |
| Operating Margin (TTM) | -0.21% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | 43.60% |
| Total Debt/Equity (MRQ) | 181.82% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | 24.23 M |
| Levered Free Cash Flow (TTM) | 38.15 M |
| Return on Assets (TTM) | -6.45% |
| Return on Equity (TTM) | -33.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Tandem Diabetes Care, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.75 |
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 108.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 63.00 (Canaccord Genuity, 285.32%) | Buy |
| Median | 24.00 (46.79%) | |
| Low | 20.00 (Mizuho, 22.32%) | Hold |
| Average | 33.70 (106.12%) | |
| Total | 4 Buy, 6 Hold | |
| Avg. Price @ Call | 20.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 01 May 2025 | 24.00 (46.79%) | Hold | 16.57 |
| 27 Feb 2025 | 33.00 (101.83%) | Hold | 21.75 | |
| Piper Sandler | 01 May 2025 | 30.00 (83.49%) | Buy | 16.57 |
| Mizuho | 10 Apr 2025 | 20.00 (22.32%) | Hold | 17.04 |
| Morgan Stanley | 05 Mar 2025 | 22.00 (34.56%) | Hold | 19.11 |
| Citigroup | 04 Mar 2025 | 24.00 (46.79%) | Hold | 19.49 |
| Goldman Sachs | 03 Mar 2025 | 24.00 (46.79%) | Hold | 20.78 |
| Wells Fargo | 03 Mar 2025 | 22.00 (34.56%) | Hold | 20.78 |
| Barclays | 28 Feb 2025 | 53.00 (224.16%) | Buy | 22.14 |
| RBC Capital | 27 Feb 2025 | 55.00 (236.39%) | Buy | 21.75 |
| Canaccord Genuity | 26 Feb 2025 | 63.00 (285.32%) | Buy | 33.59 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | Tandem Diabetes Care Announces First Quarter 2025 Financial Results |
| 03 Apr 2025 | Announcement | Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025 |
| 19 Mar 2025 | Announcement | Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes |
| 18 Mar 2025 | Announcement | Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States |
| 26 Feb 2025 | Announcement | Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance |
| 25 Feb 2025 | Announcement | Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes |
| 13 Feb 2025 | Announcement | Tandem Diabetes Care Announces Upcoming Conference Presentations |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |